WallStreetZenWallStreetZen

NASDAQ: XGN
Exagen Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for XGN

Based on 1 analyst offering 12 month price targets for Exagen Inc.
Min Forecast
$7.00+152.71%
Avg Forecast
$7.00+152.71%
Max Forecast
$7.00+152.71%

Should I buy or sell XGN stock?

Based on 1 analyst offering ratings for Exagen Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their XGN stock forecasts and price targets.

XGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-14

1 of 1

Forecast return on equity

Is XGN forecast to generate an efficient return?
Company
-73.16%
Industry
-2.66%
Market
49.6%
XGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is XGN forecast to generate an efficient return on assets?
Company
-26.09%
Industry
10.11%
XGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

XGN earnings per share forecast

What is XGN's earnings per share in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.03
Avg 2 year Forecast
-$0.74

XGN revenue forecast

What is XGN's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$57.1M+0.69%
Avg 2 year Forecast
$64.9M+14.45%
XGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

XGN revenue growth forecast

How is XGN forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
0.69%
Industry
4.66%
Market
10%
XGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
XGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

XGN vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
XGN$2.77$7.00+152.71%Strong Buy
NOTV$1.78$5.25+194.94%Hold
PRPH$2.63N/AN/A
OCX$3.11$4.42+42.03%Buy
PRE$4.65$9.00+93.55%Strong Buy
View Top Diagnostic & Research Stocks

Exagen Stock Forecast FAQ

Is Exagen Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: XGN) stock is to Strong Buy XGN stock.

Out of 1 analyst, 1 (100%) are recommending XGN as a Strong Buy, 0 (0%) are recommending XGN as a Buy, 0 (0%) are recommending XGN as a Hold, 0 (0%) are recommending XGN as a Sell, and 0 (0%) are recommending XGN as a Strong Sell.

If you're new to stock investing, here's how to buy Exagen stock.

What is XGN's earnings growth forecast for 2024-2025?

(NASDAQ: XGN) Exagen's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 45.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.18%.

Exagen's earnings in 2024 is -$17,314,000.On average, 2 Wall Street analysts forecast XGN's earnings for 2024 to be -$17,821,049, with the lowest XGN earnings forecast at -$19,298,892, and the highest XGN earnings forecast at -$16,343,206.

In 2025, XGN is forecast to generate -$12,865,928 in earnings, with the lowest earnings forecast at -$12,865,928 and the highest earnings forecast at -$12,865,928.

What is XGN's revenue growth forecast for 2024-2025?

(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 0.69% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.

Exagen's revenue in 2024 is $56,660,000.On average, 2 Wall Street analysts forecast XGN's revenue for 2024 to be $991,893,492, with the lowest XGN revenue forecast at $991,024,173, and the highest XGN revenue forecast at $992,762,812.

In 2025, XGN is forecast to generate $1,127,507,327 in revenue, with the lowest revenue forecast at $1,117,944,813 and the highest revenue forecast at $1,137,069,841.

What is XGN's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: XGN) forecast ROA is -26.09%, which is lower than the forecast US Diagnostics & Research industry average of 10.11%.

What is XGN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year XGN price target, the average XGN price target is $7.00, with the highest XGN stock price forecast at $7.00 and the lowest XGN stock price forecast at $7.00.

The Wall Street analyst predicted that Exagen's share price could reach $7.00 by May 14, 2025. The average Exagen stock price prediction forecasts a potential upside of 152.71% from the current XGN share price of $2.77.

What is XGN's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: XGN) Exagen's current Earnings Per Share (EPS) is -$0.97. On average, analysts forecast that XGN's EPS will be -$1.03 for 2024, with the lowest EPS forecast at -$1.11, and the highest EPS forecast at -$0.94. In 2025, XGN's EPS is forecast to hit -$0.74 (min: -$0.74, max: -$0.74).

What is XGN's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: XGN) forecast ROE is -73.16%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.